A5010946005- Medical Imaging Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Cancer Immunotherapy and Biomarkers
- Parathyroid Disorders and Treatments
- Radiopharmaceutical Chemistry and Applications
- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Medical Imaging and Pathology Studies
- CAR-T cell therapy research
- Esophageal Cancer Research and Treatment
- Lung Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Gastric Cancer Management and Outcomes
- Glioma Diagnosis and Treatment
- Lung Cancer Research Studies
- Neonatal Health and Biochemistry
- Brain Metastases and Treatment
- Thyroid and Parathyroid Surgery
- Immunotherapy and Immune Responses
- Lymphadenopathy Diagnosis and Analysis
- Prostate Cancer Treatment and Research
- Hepatocellular Carcinoma Treatment and Prognosis
Memorial Sloan Kettering Cancer Center
2019-2025
Cornell University
2020-2025
New York Hospital Queens
2016-2024
Columbia University Irving Medical Center
2016-2024
NewYork–Presbyterian Hospital
2016-2024
Hoag Memorial Hospital Presbyterian
2022
Brigham and Women's Hospital
2021
Dana-Farber Cancer Institute
2021
Presbyterian Hospital
2020
Columbia University
2016-2020
BACKGROUND. Some countries have limited the maximum allowable storage duration for red cells to 5 weeks before transfusion. In US, blood can be stored up 6 weeks, but randomized trials not assessed effects of this final week on clinical outcomes.
Background There currently is no consensus on the optimal localization procedure and imaging protocol for parathyroid adenoma. Parathyroid four-dimensional (4D) CT has emerged as a promising method preoperative localization. Purpose To evaluate diagnostic performance of 4D technetium 99m-sestamibi (hereafter, referred to sestamibi) SPECT/CT in patients with primary hyperparathyroidism. Materials Methods This was single-institution retrospective study hyperparathyroidism who underwent...
BACKGROUND. Glucose-6-phosphate dehydrogenase (G6PD) deficiency decreases the ability of red blood cells (RBCs) to withstand oxidative stress. Refrigerated storage RBCs induces We hypothesized that G6PD-deficient donor would have inferior quality for transfusion as compared with G6PD-normal RBCs.
Radioimmunoconjugates targeting human epidermal growth factor receptor 2 (HER2) have shown potential to noninvasively visualize HER2-positive tumors. However, the stochastic approach that has been traditionally used radiolabel these antibodies yields poorly defined and heterogeneous products with suboptimal in vivo performance. Here, we describe a first-in-human PET study on patients breast cancer evaluating safety, biodistribution, dosimetry of <sup>89</sup>Zr-site-specific...
Background Human epidermal growth factor receptor 2 (HER2)-targeted therapies are successful in patients with HER2-positive malignancies; however, spatial and temporal heterogeneity of HER2 expression may prevent identification optimal for these therapies. Purpose To determine whether imaging the HER2-targeted PET tracer zirconium 89 (89Zr)-pertuzumab can depict metastases women HER2-negative primary breast cancer. Materials Methods From January to June 2019, biopsy-proven cancer metastatic...
Background Lung chemoembolization is an emerging treatment option for lung tumors, but the optimal embolic, drug, and technique are unknown. Purpose To determine technical success rate safety of bronchial or pulmonary artery metastases using ethiodized oil, mitomycin, microspheres. Materials Methods Patients with unresectable unablatable lung, endobronchial, mediastinal metastases, who failed systemic chemotherapy, were enrolled in this prospective, single-center, single-arm, phase I...
Summary Histiocytic neoplasms are diverse clonal haematopoietic disorders, and clinical disease is mediated by tumorous infiltration as well uncontrolled systemic inflammation. Individual subtypes include Langerhans cell histiocytosis (LCH), Rosai–Dorfman–Destombes (RDD) Erdheim–Chester (ECD), these have been characterized with respect to phenotypes, driver mutations treatment paradigms. Less known about patients mixed histiocytic (MXH), that two or more coexisting disorders. This...
9082 Background: Objective response rates (ORR) to chemotherapy beyond the first-line for advanced NSCLC are low (5-10%). Pre-clinical studies suggest that some chemotherapies may act, in part, through immune mediated mechanisms. Additionally, results from phase I/II of combined with checkpoint inhibitors (ICIs) high ( > 50%) and potential synergy. It is unknown whether more efficacious when given after ICIs. Methods: We reviewed demographics, imaging, treatment history, clinical course...